On August 23, 2013 the paper “Treatment of early caries lesions using biomimetic self-assembling peptides – a clinical safety trial” describing research led by Professors Paul Brunton and Jennifer Kirkham and Dr Amalia Aggeli from the University of Leeds was published in the British Dental Journal, part of the renowned Nature Publishing Group. The study shows the safety and efficacy of the early caries therapy with P11-4 – the main component of Curodont™ Repair.
The study is an integral part of the clinical program evaluating the efficacy of Curodont™ Repair and has indicated that biomimetic mineralisation is an effective tool in the treatment of early tooth decay.
„The Self-Assembling Peptide Technology investigated has the potential for widespread applications in dentistry offering novel therapeutic treatments that will be of great benefit to patients” says Prof. Paul Brunton, principle clinical investigator of the study.
Open Access Publication: http://www.nature.com/bdj/journal/v215/n4/pdf/sj.bdj.2013.741.pdf
About Curodont™ and Curolox™ Technologies
The patented Curolox™ technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
Curodont™ Repair provides dentists with a non-invasive option for natural mineralisation rather than classical repair of carious lesions. Applied to an early lesion, Curodont™ Repair forms a scaffold within the lesion to allow new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the lesion will mineralise within several weeks. This effect is observed in a growing number of patients both in clinical studies and daily practice settings. Curodont™ Repair shows tremendous potential in the treatment of early dental caries.
Curodont™ Protect uses the Curolox™ technology to protect the tooth surface from acid attack and to treat unpleasant tooth sensitivity. According to CEO, Dominik Lysek, “Curodont™ Protect has its main benefit in prophylaxis and in the treatment of dentin hypersensitivity.”
The clinical data obtained in proof-of-concept clinical studies present a milestone for credentis, demonstrating product safety, patient acceptability and successful treatment of early tooth decay. credentis, with its regenerative product line, launches a trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions, avoiding frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in the Technopark, Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Fund, Aargauer Forschungsfond and the Medical Technologies IKC together with the University of Leeds.
Dr. Dominik Lysek, CEO; Michael Hug, CTO; and Tobias Feger, CBO, have a strong track record in medical technology, marketing and networking in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.
